Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06673329 · ClinicalTrials.gov registry record · Phase 1
Brodalumab in the Treatment of Immune-Related Adverse Events
A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by Brian Henick, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT06673329 is a Phase 1 study of Breast Cancer and Lung Cancer that is actively recruiting participants, run by Brian Henick, MD. The registered enrollment target is 11 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06673329, a Phase 1 study of Breast Cancer and Lung Cancer, is actively recruiting participants, sponsored by Brian Henick, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.
Conditions Studied
Interventions
- DRUG Brodalumab
- RADIATION CT scan
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06673329
The ClinicalTrials.gov registry entry for NCT06673329 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Brian Henick, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Brodalumab is the first listed.
NCT06673329 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06673329 about?
NCT06673329 is a clinical study titled "Brodalumab in the Treatment of Immune-Related Adverse Events". The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study i...
What is the current status of trial NCT06673329?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2025-03-11. Estimated completion is 2026-11.
What conditions does trial NCT06673329 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Pancreatic Cancer, Esophageal Cancer, Colon Cancer.
What interventions are being tested in trial NCT06673329?
The interventions under investigation include: Brodalumab (DRUG), CT scan (RADIATION).
Who is sponsoring clinical trial NCT06673329?
This trial is sponsored by Brian Henick, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06673329 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.